Total white blood count at AML diagnosis was higher in patients with FLT3 mutation (64.7 vs. 7.8×109/L, p=0.0004), NPM1 mutation (35.9 vs. 6.2×109/L, p<0.0001), and DNMT3A mutation (29.5 vs. 7.7×109/L, p=0.001), whereas it was lower in patients with IDH2 mutation (2.9 vs. 10.9×109/L, p=0.04) and RUNX1 mutation (3.0 vs. 12.4×109/L, p=0.02). This evidence concerns the gene FLT3 and acute myeloid leukemia.